Biotech Funding, Editing, and Policy
Kilder
- Endpoints: Sling gets $123M for Phase 3 trial of ex-Astellas drug in thyroid eye disease
- Fierce Biotech: Sling reels in $123M series C to fund oral Tepezza rival through phase 3 trial - Fierce Biotech
- BioPharma Dive: Sling banks $123M for an experimental thyroid eye disease pill - biopharmadive.com
- GEN: Prime Assembly Expands Genome Editing with Precise, Large-Scale DNA Integration
- Nature: Targeted genomic integration and rearrangement using prime assembly - Nature
- GEN: Cellares and GenomeFrontier Therapeutics Partner to Advance Automated Manufacturing of GF-CART01 - genengnews.com
- BioPharma Dive: Skyhawk racks up more support for Huntington’s drug
- Finance: Skyhawk Therapeutics Announces Final Fifteen-Month Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease Patients - Yahoo Finance
- STAT: STAT+: Sen. Warren demands to see Trump drug-pricing pharma contracts, accuses RFK Jr. of hiding them
- BioSpace: AI is changing the talent biotech companies compete to hire
- Eu: Mid-Hire Candidate Poaching & Long-Term Vacant Roles: What Do the Unpoachable Top Leading Talents in AI Pharmaceutical Companies Look Like? - 36Kr
- Labiotech: Oncology biotech news: key moves to watch in September 2026
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.